Recruiting

Tau PET/CT

Sponsor:

University of Pennsylvania

Code:

NCT05658913

Conditions

Alzheimer's Disease

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

AV-1451

Study Details

Brief summary:

To collect Tau PET/CT imaging in older adults diagnosed with Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) in the Mismatch Prospective Cohort Study (MPC-Tau) study to determine relationship to clinical, cognitive, and other biomarker data. Findings from this study will likely provide insight into the phenotypic variability of Alzheimer's Disease and other related pathologies.

Conditions

Alzheimer's Disease

Study ID

NCT05658913

Start date

Mar 14, 2023

Status verified date

Sep, 2026

Completion date

Dec, 2029

Anticipated

Primary completion date

Dec, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Enrolled in MPC study (Protocol 850160 at UPenn; Protocol 2022P002447 at MGH).
2. Reliable study partner to accompany participant to the PET/CT scan
3. A brain MRI must be performed within 6 months prior to their study AV-1451 TAU PET/CT scan date and be deemed of adequate quality that the scan may be used for study analysis, including 3T high-resolution imaging of medial temporal lobe structures.

Exclusion Criteria:

1. Have any medical or psychiatric conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study.
2. Have evidence of structural abnormalities such as major stroke or mass on MRI that is likely to interfere with analysis of the PET/CT scan.
3. Inability to tolerate or contraindication to imaging procedures in the opinion of an investigator or treating physician.
4. Have a history of significant ongoing alcohol or substance abuse based on self- report.
5. Female participants of child-bearing age will not be able to participate in this study, determined by self-report.

Study Design

Enrollment

100 participants

Anticipated

Interventions and Outcome Measures

Interventions

AV-1451

This is a cross-sectional study using the radiotracer AV-1451 to determine the relationship of tau pathology to other biomarker data of MPC participants.

Primary outcome measure

  • Clusters based on spatial pattern and extent of T-N Mismatch [ Time Frame: 5 years ]

Central Contacts and Locations

Locations

Massachusetts General Hospital

Recruiting

Boston, Massachusetts, United States, 02114-2696

Contacts

Principal Investigator:

Bradford Dickerson, MD

University of Pennsylvania

Recruiting

Philadelphia, Pennsylvania, United States, 19104

Contacts

Principal Investigator:

David Wolk, MD

More Information

Sponsor

University of Pennsylvania

Last update posted

Sep 4, 2026

Last verified

Sep, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by University of Pennsylvania on 2026-09-04.